Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases

JAMA

Volumn 292, Issue 4, 2004, Pages 490-495

  Hofbauer, Lorenz C ^a   Schoppet, Michael ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GLUCOCORTICOID; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOCLAST DIFFERENTIATION FACTOR RECEPTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG; CARRIER PROTEIN; CELL RECEPTOR; GLYCOPROTEIN; LIGAND; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RECOMBINANT PROTEIN; TNFRSF11A PROTEIN, HUMAN; TNFRSF11B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

BONE CANCER; BONE DISEASE; BONE METASTASIS; BONE REMODELING; CELL ACTIVATION; CHRONIC INFLAMMATION; CLINICAL TRIAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG USE; ESTROGEN DEFICIENCY; FEMALE; HUMAN; MYELOMA; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; VASCULAR DISEASE; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; BONE DISEASES; BONE REMODELING; BONE RESORPTION; CARRIER PROTEINS; GLYCOPROTEINS; HUMANS; LIGANDS; MEMBRANE GLYCOPROTEINS; OSTEOCLASTS; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT PROTEINS; VASCULAR DISEASES;

EID: 3242781731     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.292.4.490     Document Type: Review

References (51)

1. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-1508.
2. Lacey DL, Timms E, Tan H-L, et al. Osteoprotegerin (OPG) ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93: 165-176.
3. Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A. 1999; 96:3540-3545.
4. Simonet WS, Lacey DL, Dunstan CR, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-319.
5. Hofbauer LC, Khosla S, Dunstan CR, et al. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140:4367-4370.
6. Viereck V, Gründker C, Blaschke S, et al. Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. J Clin Endocrinol Metab. 2003;88:4206-4213.
7. Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111:1221-1230.
8. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc Natl Acad Sci U S A. 2000;97:7829-7834.
9. Hofbauer LC, Gori F, Riggs BL, et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells. Endocrinology. 1999;140: 4382-4389.
10. Sasaki N, Kusano E, Ando Y, et al. Glucocorticoid decreases circulating osteoprotegerin (OPG). Nephrol Dial Transplant. 2001;16:479-482.
11. Fahrleitner A, Prenner G, Leb G, et al. Serum osteoprotegerin is a major determinant of bone density development and prevalent vertebral fracture status following cardiac transplantation. Bone. 2003;32:96-106.
12. Locklin RM, Khosla S, Turner RT, Riggs BL. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem. 2003;89:180-190.
13. Kong Y-Y, Feige U, Sarosi I, et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999; 402:304-309.
14. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J Immunol. 2003;170:2655-2662.
15. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. Arthritis Rheum. 2002;46:1744-1753.
16. Teng Y-TA, Nguyen H, Gao X, et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest. 2000;106:R59-R67.
17. Zwerina J, Hayer S, Tohidast-Akrad M, et al. Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis. Arthritis Rheum. 2004;50: 277-290.
18. Sezer O, Heider U, Zavrski I, Kühne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood. 2003;101:2094-2098.
19. Giuliani N, Bataille R, Mancini C, et al. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood. 2001;98:3527-3533.
20. Heider U, Langelotz C, Jakob C, et al. Expression of receptor activator of NF-κB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma. Clin Cancer Res. 2003;9:1436-1440.
21. Standal T, Seidel C, Hjertner O, et al. Osteoprotegerin is bound, internalized and degraded by multiple myeloma cells. Blood. 2002;100:3002-3007.
22. Seidel C, Hjertner O, Abildgaard N, et al, for the Nordic Myeloma Study Group. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood. 2001;98:2269-2271.
23. Terpos E, Szydlo R, Apperley JF, et al. Soluble receptor activator of nuclear factor κB ligand-osteoprotegerin ratio predicts survival in multiple myeloma. Blood. 2003;102:1064-1069.
24. Michigami T, Ihara-Watanabe M, Yamazaki M, Ozono K. Receptor activator of nuclear factor κB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. Cancer Res. 2001;61:1637-1644.
25. Nagai M, Kyakumoto S, Sato N. Cancer cells responsible for humoral hypercalcemia express mRNA enclosing a secreted form of ODF/TRANCE that induces osteoclast formation. Biochem Biophys Res Commun. 2000;269:532-536.
26. Thomas RJ, Guise TA, Yin JJ, et al. Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology. 1999;140:4451-4458.
27. Oyajobi BO, Anderson DM, Traianedes K, et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor κB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572-2578.
28. Holen I, Croucher PI, Hamdy FC, Eaton CL. Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 2002;62: 1619-1623.
29. Honore P, Luger NM, Sabino MA, et al. Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med. 2000; 6:521-528.
30. Menaa C, Reddy SV, Kurihara N, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest. 2000; 105:1833-1838.
31. Hughes AE, Ralston SH, Marken J, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet. 2000;24:45-48.
32. Whyte MP, Hughes AE. Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis. J Bone Miner Res. 2002; 17:26-29.
33. Whyte MP, Obrecht SE, Finnegan PM, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med. 2002;347:175-184.
34. Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. J Exp Med. 2000;192:463-474.
35. Price PA, June HH, Buckley JR, Williamson MK. Osteoprotegerin inhibits artery calcification induced by warfarin and by vitamin D. Arterioscler Thromb Vasc Biol. 2001;21:1610-1616.
36. Hofbauer LC, Shui C, Riggs BL, et al. Effects of immunosuppressants on receptor activator of NF-κB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. Biochem Biophys Res Commun. 2001;280:334-339.
37. 3-induced, NF-κB-dependent survival factor for endothelial cells. J Biol Chem. 2000;275:20959-20962.
38. Jono S, Ikari Y, Shioi A, et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106:1192-1194.
39. Schoppet M, Sattler AM, Schaefer JR, et al. Increased osteoprotegerin serum levels in men with coronary artery disease. J Clin Endocrinol Metab. 2003; 88:1024-1028.
40. Browner WS, Lui LY, Cummings SR. Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. J Clin Endocrinol Metab. 2001;86:631-637.
41. Kiechl S, Schett G, Wenning G, et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004;109: 2175-2180.
42. Rogers A, Saleh G, Hannon RA, et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002;87:4470-4475.
43. Yano K, Tsuda E, Washida N, et al. Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor. J Bone Miner Res. 1999;14:518-527.
44. Brown JM, Vessella RL, Kostenuik PJ, et al. Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res. 2001; 7:2977-2983.
45. Schett G, Kiechl S, Redlich K, et al. Soluble RANKL and risk of nontraumatic fracture. JAMA. 2004;291: 1108-1113.
46. Cheng X, Kinosaki M, Takami M, et al. Disabling of receptor activator of nuclear factor-κB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. J Biol Chem. 2004;279:8269-8277.
47. Kobayashi Y, Hashimoto F, Miyamoto H, et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor β and osteoprotegerin expression. J Bone Miner Res. 2000;15:1924-1934.
48. Onyia JE, Galvin RJ, Ma YL, et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther. 2004;309:369-379.
49. Bekker PJ, Holloway D, Nakanishi A, et al. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16:348-360.
50. Body JJ, Greipp P, Coleman RE, et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003;97(3 suppl):887-892.
51. Bekker PJ, Holoway DL, Rasmussen AS, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19: 1059-1066.